Marina Biotech, a nucleic acid-based drug discovery and development company, will be closing its Cambridge, Mass., site and consolidating all R&D efforts at its headquarters in Bothell, Wash.

"This move will not affect the START-FAP trial as noted by our announcement of cohort II dosing. Further, we expect to continue to develop the tkRNAi platform in our labs in Bothell," said J. Michael French, president and CEO of Marina Biotech.

The individuals affected by the decision were all part of the former Cequent team, who helped develop CEQ508 and executed the START-FAP trial.

“I want to thank them for their efforts and wish them all well in their future endeavors," added French.